Posted in | News

CEMEX Completes Construction of First Phase of Managua Grinding Plant

CEMEX, S.A.B. de C.V. (“CEMEX”) announced today that its subsidiary CEMEX Latam Holdings, S.A. ("CLH") (BVC:CLH) has completed the construction of the first phase of a new cement grinding plant in Ciudad Sandino, Managua.

CLH invested approximately U.S.$30 million for infrastructure procurement and the installation of the first cement grinding mill, with an annual production capacity of approximately 220,000 metric tons. The inauguration ceremony took place this Thursday, August 27, at the new facility and was attended by the President of Nicaragua, Daniel Ortega, and the Chief Executive Officer of CEMEX, Fernando A. Gonzalez.

The second phase, which is expected to be completed by the end of 2017, will include the installation of a second cement grinding mill with an additional annual production capacity of approximately 220,000 metric tons and an additional investment of approximately U.S.$25 million. Upon completion of the second phase, CEMEX Nicaragua is expected to reach an estimated total annual cement production capacity of approximately 860,000 metric tons.

“The positive business outlook in Nicaragua strengthens our commitment to be a reliable supplier given the growing need for high quality building materials required for public infrastructure, commercial projects, and housing in the country,” said Fernando A. Gonzalez.

CEMEX is a global building materials company that provides high-quality products and reliable services to customers and communities in more than 50 countries. CEMEX has a rich history of improving the well-being of those it serves through innovative building solutions, efficiency advancements, and efforts to promote a sustainable future. For more information, please visit www.cemex.com

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.